Cancer research, in the genome era, is undergoing a dramatic and rapid metamorphosis. But the new discoveries in cancer biology and genetics must be translated properly into cancer practice through sound research. Unfortunately, academically prepared clinician investigators, to conduct such research, are in short supply. The NCI's program announcement PAR 99-077, """"""""Clinical Oncology Research Career Development Program,"""""""" is designed to increase the number of medical doctors and doctorally degreed oncology nurses to serve this clinical-translational interface. Mayo Clinic is a highly respected center for medical training, research and patient care. The Mayo environment has the key elements needed for an outstanding training program in clinical-translational research: The Mayo Clinic Cancer Center (MCCC), an NCI-designated comprehensive cancer center, has had continuous funding from NCI for over 25 years - the center is vital and growing, experiencing a 250% increase in its NCI funding since 1994. It is recognized that particularly for the quality of its clinical research, clinical trials, and translational research; Mayo is world-renowned as a center for medical training - its Graduate School of Medicine is the largest residency training program in the world, teaching 1200 physicians each year in over 100 specialties; and Mayo has an outstanding K30 program, delivering the didactic elements necessary for clinical-translational research training. With the proposed Mayo Clinical Oncology Research Training Program, we will build upon our Comprehensive Cancer Center and K30 infrastructures to develop a combined didactic-mentored training program in clinical and translational cancer research. This proposed program represents the first cancer research training program for clinicians at Mayo. We have brought together an exceptional group of researchers and mentors, organized in already existing multidisciplinary teams. Research plans for fellows can be designed in breast cancer, GI cancer, genetics/family studies, hematology, neuro-oncology, nicotine dependence, novel therapeutics, ovarian cancer, population sciences/outcomes research, prostate cancer, and symptom control/QOL. With this program, we will train clinician investigators who will have a solid understanding of high quality clinical research, who can design and manage all phases of clinical trials, and who can partner with basic, population and/or behavioral scientists to translate discoveries into better medical care.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Physician Scientist Award (Program) (PSA) (K12)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-GRB-T (J1))
Program Officer
Lei, Ming
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mayo Clinic, Rochester
United States
Zip Code
Yan, Yiyi; Kumar, Anagha Bangalore; Finnes, Heidi et al. (2018) Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy. Front Immunol 9:1739
Miao, Diana; Margolis, Claire A; Gao, Wenhua et al. (2018) Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science 359:801-806
Mansfield, Aaron S; Peikert, Tobias; Vogelzang, Nicholas J et al. (2018) Effects of Reduction in Tumor Burden on Survival in Epithelioid Malignant Pleural Mesothelioma. Mayo Clin Proc 93:1026-1033
Haddad, Tufia C; D'Assoro, Antonino; Suman, Vera et al. (2018) Phase I trial to evaluate the addition of alisertib to fulvestrant in women with endocrine-resistant, ER+ metastatic breast cancer. Breast Cancer Res Treat 168:639-647
Painuly, Utkarsh; Ramakrishnan, Vijay; Kimlinger, Teresa et al. (2018) Aurora kinase and FGFR3 inhibition results in significant apoptosis in molecular subgroups of multiple myeloma. Oncotarget 9:34582-34594
Kim, Minjee; Ma, Daniel J; Calligaris, David et al. (2018) Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood-Brain Barrier. Mol Cancer Ther 17:1893-1901
Paludo, Jonas; Fritchie, Karen; Haddox, Candace L et al. (2018) Extraskeletal Osteosarcoma: Outcomes and the Role of Chemotherapy. Am J Clin Oncol 41:832-837
Durani, Urshila; Gallo de Moraes, Alice; Beachey, Joel et al. (2018) Epithelioid angiosarcoma: A rare cause of pericarditis and pleural effusion. Respir Med Case Rep 24:77-80
Parikh, Sameer A; Chaffee, Kari G; Larson, Melissa C et al. (2018) Outcomes of a large cohort of individuals with clinically ascertained high-count monoclonal B-cell lymphocytosis. Haematologica 103:e237-e240
Yan, Yiyi; Cao, Siyu; Liu, Xin et al. (2018) CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy. JCI Insight 3:

Showing the most recent 10 out of 243 publications